argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.
| Date | Status | Outer | Rating | Price |
|---|---|---|---|---|
| Aug-04-26 | Resumed | Guggenheim | Buy | $1185 |
| Mar-10-26 | Upgrade | Deutsche Bank | Hold → Buy | |
| Dec-18-25 | Downgrade | Robert W. Baird | Outperform → Neutral | $858 |
| Nov-24-25 | Downgrade | Wolfe Research | Outperform → Peer Perform | |
| Sep-15-25 | Resumed | Truist | Buy | $918 |
| Sep-11-25 | Downgrade | Deutsche Bank | Buy → Hold | |
| Aug-25-25 | Initiated | RBC Capital Mkts | Outperform | $850 |
| Jul-08-25 | Upgrade | Deutsche Bank | Hold → Buy | |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight | $700 |
| May-13-25 | Upgrade | Robert W. Baird | Neutral → Outperform | $680 |
| Mar-17-25 | Upgrade | Bernstein | Mkt Perform → Outperform | |
| Mar-12-25 | Upgrade | Deutsche Bank | Sell → Hold | |
| Jan-17-25 | Downgrade | Deutsche Bank | Hold → Sell | |
| Nov-12-24 | Upgrade | Wolfe Research | Peer Perform → Outperform | $697 |
| Nov-05-24 | Upgrade | Scotiabank | Sector Perform → Sector Outperform | $715 |
| Nov-01-24 | Upgrade | William Blair | Mkt Perform → Outperform | |
| Nov-01-24 | Downgrade | Robert W. Baird | Outperform → Neutral | $515 → $650 |
| Oct-10-24 | Resumed | Raymond James | Strong Buy | $605 |
| Oct-04-24 | Downgrade | Deutsche Bank | Buy → Hold | |
| Aug-06-24 | Upgrade | Barclays | Equal Weight → Overweight |